We can’t show the full text here under this license. Use the link below to read it at the source.
mRNA-encoded mutant HPV16/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice
Mutant HPV16/18 mRNA vaccines trigger targeted T-cell responses and work with anti-PD-1 therapy to shrink tumors in mice
AI simplified
Abstract
The mRNA-based therapeutic vaccine MTS107 induced potent antitumor activity in HPV16 and HPV18 mouse models.
- The vaccine effectively targeted dendritic cells and macrophages.
- High levels of protein translation were achieved in vitro without negatively impacting p53 or pRb.
- Antitumor activity was dose-dependent and time-dependent, linked to the expansion of HPV-specific .
- Combining the vaccine with an anti-PD-1 antibody resulted in complete tumor remission.
AI simplified
Key numbers
71.79%
Tumor Growth Inhibition at High Dose
achieved with 5 µg dose of P016-2 vaccine in HPV18MC38 model.
100%
Complete Tumor Remission Rate
Achieved with P016-2 vaccine combined with α in HPV18 model.
58.11%
Tumor Growth Inhibition at Low Dose
achieved with 10 µg dose of P016-2 vaccine in late-stage model.